Patient groups call attention to skin condition commonly known as hives Urticaria Day 2025 Raising awareness of hives ...

Novartis gains FDA approval for Rhapsido, the first oral BTK inhibitor for Chronic Spontaneous Urticaria, offering new hope ...

Remibrutinib is the first Bruton tyrosine kinase inhibitor approved by the FDA for chronic spontaneous urticaria.

When those itchy welts won’t go away, you may have chronic spontaneous urticaria (CSU). Here’s everything you need to know to ...

The FDA approved oral remibrutinib (Rhapsido) as a second-line treatment for chronic spontaneous urticaria (CSU), or chronic ...

Novartis AG won US approval for a new treatment for a hives-like skin condition, bolstering the Swiss drugmaker’s push into ...

The FDA approved remibrutinib, the first oral treatment for adults with persistent chronic spontaneous urticaria despite H1 ...

The first oral BTK blocker for chronic spontaneous urticaria, Rhapsido offers a more convenient treatment option for patients ...

The Food and Drug Administration (FDA) has approved Rhapsido ® (remibrutinib) for the treatment of chronic spontaneous urticaria (CSU) in adult patients who remain symptomatic despite H 1 ...

France's Sanofi said its Dupixent drug jointly developed with Regeneron advanced toward a new indication for chronic hives in the European Union, while the U.S. Food and Drug Administration extended ...

Rhapsido is the first and only Bruton’s tyrosine kinase (BTK) inhibitor approved for chronic spontaneous urticaria (CSU).

Treatment for chronic hives lasting at least 6 weeks may include one or more types of medication, as well as certain lifestyle changes.